{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-093882","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2025-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.500329+00:00","generated_at":"2026-05-17T05:34:03.343802+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptimmune granted Nasdaq extension to Dec 1, 2025 to regain $1 bid compliance","bullets":["Nasdaq Hearings Panel granted exception until December 1, 2025 to meet minimum $1.00 bid price per share.","Notice received on September 22, 2025; failure to comply by deadline will lead to delisting of ADSs.","If non-compliant by December 1, 2025, trading will be suspended and delisting proceedings will commence."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-093882","json":"https://secwatch.observer/filing/0001104659-25-093882.json","markdown":"https://secwatch.observer/filing/0001104659-25-093882.md","text":"https://secwatch.observer/filing/0001104659-25-093882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/0001104659-25-093882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/adap-20250922x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:34:03.343802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d091205c4e04773221ba60c4f44bef01847820c","claim":"Adaptimmune Therapeutics PLC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"September 22, 2025, Adaptimmune Therapeutics plc (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) confirming that the Company has been granted an exception period to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). ​ The Company has until December 1, 2025 to regain compliance with the Bid Price Rule. Failure to regain compliance by December 1, 2025 will result in the delisting of the Company’s American Depositary Shares from The Nasdaq Capital Market. ​ Forward-Looking Stat","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/0001104659-25-093882-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}